Health Care • Biotechnology: Pharmaceutical Preparations
$4.57 ▼ -0.08
(-1.72%)
MKT CAP: $18.8M • VOL: 24.4K
52W L $4 52W H $11
ROARABLE / RQD
E • 32/100
PIOTROSKI
4 / 9
KYNB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.4M | $29.6M | $46.8M |
| YoY Revenue Growth % | -78.3% | -36.7% | — |
| Gross Profit | $5.9M | $14.1M | — |
| Gross Margin % | 91.4% | 47.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$45.9M | -$150.4M | -$322.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | $183.5M | -$47.6M | -$284.2M |
| EBITDA (Normalized) | -$45.9M | -$150.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.8M | -$138.0M | -$315.0M |
| Capital Expenditures (CapEx) | $38.0K | $266.0K | — |
| Free Cash Flow (FCF) | -$4.8M | -$138.3M | -$315.0M |
| FCF Margin % | -74.7% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $47.9M | $50.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$30.0M | -$225.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KYNB.